Folger Nolan Fleming Douglas Capital Management Inc. Has $25.43 Million Position in Johnson & Johnson $JNJ

Folger Nolan Fleming Douglas Capital Management Inc. grew its holdings in Johnson & Johnson (NYSE:JNJ) by 3.9% in the 1st quarter, according to the company in its most recent filing with the SEC. The firm owned 104,039 shares of the company’s stock after buying an additional 3,864 shares during the quarter. Johnson & Johnson makes up about 2.3% of Folger Nolan Fleming Douglas Capital Management Inc.’s investment portfolio, making the stock its 10th largest holding. Folger Nolan Fleming Douglas Capital Management Inc.’s holdings in Johnson & Johnson were worth $25,431,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Brighton Jones LLC lifted its holdings in Johnson & Johnson by 13.9% in the fourth quarter. Brighton Jones LLC now owns 51,876 shares of the company’s stock worth $7,502,000 after buying an additional 6,332 shares during the period. United Bank grew its holdings in shares of Johnson & Johnson by 110.7% during the 1st quarter. United Bank now owns 9,279 shares of the company’s stock worth $1,539,000 after acquiring an additional 4,876 shares during the period. Sivia Capital Partners LLC raised its position in shares of Johnson & Johnson by 13.4% in the 2nd quarter. Sivia Capital Partners LLC now owns 5,863 shares of the company’s stock worth $896,000 after acquiring an additional 692 shares in the last quarter. Wealth Group Ltd. raised its position in shares of Johnson & Johnson by 12.8% in the 2nd quarter. Wealth Group Ltd. now owns 1,482 shares of the company’s stock worth $226,000 after acquiring an additional 168 shares in the last quarter. Finally, Schnieders Capital Management LLC. lifted its stake in shares of Johnson & Johnson by 9.8% in the 2nd quarter. Schnieders Capital Management LLC. now owns 73,680 shares of the company’s stock valued at $11,255,000 after purchasing an additional 6,584 shares during the period. 69.55% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts recently weighed in on the company. Guggenheim upped their price target on Johnson & Johnson from $266.00 to $270.00 and gave the stock a “buy” rating in a research note on Friday, June 26th. Leerink Partners raised Johnson & Johnson from a “market perform” rating to an “outperform” rating and set a $265.00 price objective for the company in a research report on Wednesday, May 13th. Johnson Rice set a $270.00 target price on shares of Johnson & Johnson in a report on Friday, June 26th. Royal Bank Of Canada reaffirmed an “outperform” rating and issued a $265.00 target price on shares of Johnson & Johnson in a research report on Wednesday, April 15th. Finally, Raymond James Financial lifted their price target on shares of Johnson & Johnson from $237.00 to $258.00 and gave the company an “outperform” rating in a research report on Wednesday, April 15th. Twenty research analysts have rated the stock with a Buy rating and seven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and a consensus price target of $256.70.

Johnson & Johnson Stock Up 3.4%

Shares of NYSE:JNJ opened at $262.52 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.77 and a debt-to-equity ratio of 0.46. The stock has a fifty day simple moving average of $232.98 and a two-hundred day simple moving average of $231.04. Johnson & Johnson has a 12-month low of $154.21 and a 12-month high of $263.10. The stock has a market capitalization of $631.93 billion, a price-to-earnings ratio of 30.35, a PEG ratio of 2.49 and a beta of 0.24.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, April 14th. The company reported $2.70 EPS for the quarter, topping analysts’ consensus estimates of $2.68 by $0.02. Johnson & Johnson had a return on equity of 32.60% and a net margin of 21.83%.The firm had revenue of $24.06 billion for the quarter, compared to analysts’ expectations of $23.60 billion. During the same period in the prior year, the firm posted $2.77 earnings per share. The company’s quarterly revenue was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. On average, research analysts anticipate that Johnson & Johnson will post 11.57 earnings per share for the current fiscal year.

Johnson & Johnson Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, June 9th. Investors of record on Tuesday, May 26th were given a dividend of $1.34 per share. This is a positive change from Johnson & Johnson’s previous quarterly dividend of $1.30. The ex-dividend date of this dividend was Tuesday, May 26th. This represents a $5.36 annualized dividend and a yield of 2.0%. Johnson & Johnson’s payout ratio is currently 61.97%.

Trending Headlines about Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Johnson & Johnson launched its Dual-Energy THERMOCOOL SMARTTOUCH SF cardiac ablation catheter platform in Europe, expanding access for electrophysiologists and adding another potential growth driver for its med-tech business. Johnson & Johnson (JNJ) Launches Dual-Energy Cardiac Ablation Catheter in Europe
• Positive Sentiment: The company is drawing attention as a top dividend and defensive healthcare name, with articles highlighting its reliable payout, global healthcare reach, and appeal to income-focused investors. Is It Worth Investing in Johnson & Johnson (JNJ) Based on Wall Street’s Bullish Views?
• Positive Sentiment: Johnson & Johnson is being favored for long-term growth because management is emphasizing cancer and neuroscience, while expanding its oncology pipeline through regulatory progress in Europe and the planned Firefly Bio acquisition. Johnson & Johnson (JNJ) Expands Cancer Pipeline As Talc Verdict Eases One Risk
• Neutral Sentiment: Several articles compare J&J with other dividend and healthcare stocks or discuss passive-income strategies, but these are more general investor-interest pieces than direct company-specific catalysts. 3 Dividend Stocks to Buy Hand Over Fist in July
• Neutral Sentiment: Analysts are watching J&J’s Q2 Innovative Medicine business closely, with Stelara biosimilar pressure potentially offset by growth from newer drugs and blockbusters ahead of earnings. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch
• Negative Sentiment: One near-term risk remains biosimilar competition for Stelara, which could weigh on Innovative Medicine growth if newer products do not fully offset the pressure. J&J’s Innovative Medicine Business in Q2: Here’s What to Watch

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Kathryn E. Wengel sold 10,000 shares of Johnson & Johnson stock in a transaction dated Thursday, June 11th. The shares were sold at an average price of $241.15, for a total value of $2,411,500.00. Following the completion of the transaction, the executive vice president directly owned 114,288 shares of the company’s stock, valued at approximately $27,560,551.20. The trade was a 8.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.